Primary Insulin-like Growth Factor-1 Deficiency

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Ipsen
IpsenChina - Tianjin
1 program
mecasermin [rDNA origin] injectionN/A1 trial
Active Trials
NCT00747604Terminated1,378Est. May 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Ipsenmecasermin [rDNA origin] injection

Clinical Trials (1)

Total enrollment: 1,378 patients across 1 trials

NCT00747604Ipsenmecasermin [rDNA origin] injection

IGFD Registry: A Patient Registry for Monitoring Long-term Safety and Efficacy of Increlex

Start: Jun 2006Est. completion: May 20141,378 patients
N/ATerminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space